MediLink Therapeutics will present its next-generation TMALIN ("Tumor Microenvironment Activable LINker-payload”) platform and preclinical results of YL205, a novel antibody drug conjugate targeting NaPi2b, at the American Association for Cancer Research 2024 meeting (AACR 2024), which takes place April 5-10 in San Diego, United States. Presented studies are as follows:

Poster 1：

Title: MediLink’s TMALIN ADC linker technology: Tumor microenvironment specific extracellular and intracellular double cleavage mechanism for better efficacy and expanded target space

Session: April 9, 2024, 9:00 AM - 12:30 PM

Location: Section 28

AACR2024-TMALIN.pdf

https://aacrjournals.org/cancerres/article/84/6_Supplement/4702/740109/Abstract-4702-MediLink-s-TMALIN-ADC-linker?searchresult=1

Poster 2：

Title: Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker-payload for treatment of solid tumors

Session: April 8, 2024, 9:00 AM - 12:30 PM

Location: Section 23

AACR2024-YL205.pdf

https://aacrjournals.org/cancerres/article/84/6_Supplement/1894/736333/Abstract-1894-Preclinical-development-of-YL205-a

About MediLink Therapeutics

MediLink Therapeutics, founded in 2020, is a clinical-stage biotechnology company focused on innovating conjugated drugs. The company has developed its proprietary next-generation antibody drug conjugation technology platform TMALIN® (Tumor Microenvironment Activable Linker-payload), which provides homogeneous and stable conjugation with high DAR, thus further expanding the therapeutic index and enhancing the anti-tumor activity for ADC products. The company aims to develop better conjugating therapies for global patients.

About TMALIN

The Tumor Microenvironment Activable LINker-payload (TMALIN®) platform is the proprietary conjugating technology developed by MediLink Therapeutics. By utilizing both intracellular and extracellular cleavage mechanisms in tumor microenvironment and endosomes, the technology is featured as a high hydrophilic and homogeneous linker-payload with circulation stability and efficient payload release in tumor. An improved therapeutics index has been demonstrated in preclinical studies for the TMALIN platform. A series of ADC projects has been developed based on the technology and is now under clinical investigations.

About YL205

YL205 is a novel NaPi2b-targeted ADC based on the TMALIN platform. NaPi2b is a cell surface sodium-dependent phosphate transporter highly expressed in a range of cancers including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues. Currently, no therapy has been approved targeting NaPi2b, thus YL205 has the potential to address the huge unmet needs, and has shown promising efficacy and safety profiles in preclinical studies.